• Explore /
  • Poster
  • / Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.

Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.

Abstract Poster

Authors

null

Douglas Edward Gladstone

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Douglas Edward Gladstone , Marc Andre , Jan M. Zaucha , Sarit E. Assouline , Naresh Bellam , Nicola Cascavilla , Eric Jourdan , Amit W. Panwalkar , Caterina Patti , Clemens Schulte , Francesco Zaja , Trishna Goswami , Nairouz Elgeioushi , David Spaner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01466153

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3028)

DOI

10.1200/jco.2014.32.15_suppl.3028

Abstract #

3028

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Patrick Wayne Cobb

First Author: Mehdi Hamadani

First Author: Michinori Ogura

First Author: Wojciech Jurczak